A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1-RNA in Adults Without HIV
NCT ID: NCT06919016
Last Updated: 2025-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
45 participants
INTERVENTIONAL
2025-08-06
2027-03-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to see if the study products are safe, if people are able to take them without becoming too uncomfortable, and how a person's immune system responds to them (a person's immune system protects them from infections and disease).
Forty-five volunteers without HIV and in overall good health, aged 18 to 55 years, will be enrolled and be in this study for about 16 months (about 12 visits), Study procedures will include blood draws, injections, and the collection of white blood cells and cells from their lymph nodes.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
DV700P-RNA: 50 mcg at weeks 0, 8, and 24 DV701B1.1-RNA: 50 mcg at week 40
DV700P-RNA
Intramuscular (IM) injection
DV701B1.1-RNA
IM injection
Group 2
DV700P-RNA: 100 mcg at weeks 0, 8, and 24 DV701B1.1-RNA: 100 mcg at week 40
DV700P-RNA
Intramuscular (IM) injection
DV701B1.1-RNA
IM injection
Group 3
DV700P-RNA: 150 mcg at weeks 0, 8, and 24 DV701B1.1-RNA: 150 mcg at week 40
DV700P-RNA
Intramuscular (IM) injection
DV701B1.1-RNA
IM injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DV700P-RNA
Intramuscular (IM) injection
DV701B1.1-RNA
IM injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Can attend all clinic visits until the end of the study.
* Agrees to follow all study procedures.
* Will not join another study with experimental treatments during this trial, unless approved by both study sponsors.
* Generally healthy according to the study doctor.
* Physical exam and lab results show no major issues that could affect safety or study results.
* Agrees to discuss HIV risk and prevention.
* Hemoglobin levels: at least 11.0 g/dL for women and 13.0 g/dL for men.
* White blood cell count between 2,500 to 12,000/mm³ (higher levels okay if health is otherwise good and approved).
* Platelet count between 125,000 to 550,000/mm³.
* ALT enzyme level less than 2.5 times the upper limit of normal.
* Serum creatinine level within 1.1 times the upper limit of normal.
* Serum calcium level at least 8.5 mg/dL.
* Blood pressure within acceptable range (systolic 90-140 mmHg, diastolic 50-90 mmHg), with average below 140/90 mmHg and no single reading over 160/100 mmHg.
* Negative HIV test.
* Negative for Hepatitis C.
* Negative for Hepatitis B.
* Women who can become pregnant must use effective contraception from 21 days before joining the study until 8 weeks after the last vaccination and must have a negative pregnancy test on enrollment day.
* Women of pregnancy potential must agree not to seek pregnancy through methods like IVF from 21 days before joining the study until 8 weeks after the last vaccination.
Exclusion Criteria
* Body mass index (BMI) of 40 or higher, unless in good health and approved.
* Diabetes, unless it is well-controlled Type 2 diabetes or gestational diabetes.
* Previous or current investigational HIV vaccine recipients (placebo recipients are allowed).
* Received non-HIV investigational vaccines within the last year, unless they are now licensed or authorized.
* Immunodeficiency or medications that impair immune response, such as high-dose steroids.
* Received blood products or immunoglobulin within 16 weeks before enrollment.
* Received certain vaccines within the last 4 weeks before enrollment.
* Received other vaccines within 14 days before enrollment.
* History of myocarditis or pericarditis.
* Started allergy immunotherapy in the past year (unless stable and approved).
* Taken investigational research agents recently.
* Serious allergic reactions to any mRNA vaccine or drugs containing polyethylene glycol.
* History of hereditary or acquired angioedema.
* Any episode of hives (urticaria) within the past year.
* Chronic hives (urticaria).
* Hives previously caused by immunization.
* Bleeding disorder that would make study procedures unsafe.
* Seizures or use of seizure medications in the past 3 years.
* Absence of spleen or non-functional spleen.
* Active duty and reserve US military personnel.
* Any other significant condition that could affect safety or participation, including substance use, psychiatric disorders, recent suicide attempts, or cancer with potential for recurrence.
* Asthma that requires frequent or high-dose medication, recent emergency care, or multiple daily medications.
* History of certain immune-mediated conditions (mild, localized conditions may be okay).
* Allergy to local anesthetics like Novocaine or Lidocaine.
* Difficulty with venous access, such as history of intravenous drug use or problems with blood draws.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Department of Health and Human Services
FED
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama Medical Center (Site ID: 31788)
Birmingham, Alabama, United States
The Hope Clinic of the Emory Vaccine Center CRS (Site ID: 31440)
Decatur, Georgia, United States
Brigham and Women's Hospital (Site ID: 30007)
Boston, Massachusetts, United States
Columbia P&S CRS (Site ID: 30329)
New York, New York, United States
University of Rochester Medical Center (Site ID: 31467)
Rochester, New York, United States
University of Pittsburgh (Site ID: 1001)
Pittsburgh, Pennsylvania, United States
Vanderbilt University Medical Center (Site ID: 30352)
Nashville, Tennessee, United States
Seattle Vaccine and Prevention CRS (Site ID: 30331)
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HVTN 321
Identifier Type: -
Identifier Source: org_study_id